選択的セロトニン再吸収阻害剤は,脳卒中回復のためのセロトニン再吸収阻害剤です
Gillian Elizabeth Mead1, Cheng-Fang Hsieh, Maree Hackett
1Department of Geriatric Medicine, Royal Infirmary, Little France Crescent, Edinburgh, United Kingdom. Gillian.e.mead@ed.ac.uk
JAMA
|September 13, 2013
まとめ
選択的セロトニン再吸収阻害剤 (SSRI) は,うつ病がない場合でも,脳卒中の回復を助けることができます. しかし,現在の証拠の質は低いため,確認のために大規模な試験が必要である.
科学分野:
- 神経科学は神経科学である.
- 薬理学 薬理学とは
- 臨床神経学 臨床神経学
背景:
- 脳卒中は,長期的な障害の主な原因です.
- 脳卒中後の回復のための効果的な治療法を特定することは極めて重要です.
- 非うつ病の脳卒中生存者における抗うつ薬の役割は調査中です.
研究 の 目的:
- 選択的セロトニン再吸収阻害剤 (SSRI) が脳卒中後の回復結果を改善するかどうかを判断する.
- 脳卒中患者のSSRI使用と機能回復の関連性を評価する.
主な方法:
- 既存の研究の体系的なレビューとメタ解析.
- 脳卒中後の回復のためのSSRIを試験した試験の含有.
- 研究の質とバイアスのリスクの評価.
主要な成果:
- 予備的な発見は,脳卒中回復のためのSSRIの潜在的な利点を示唆しています.
- 回復の改善は,うつ病と診断されていない患者でも観察されました.
- 入手可能な証拠の質の有意な異質性と限界が特定されました.
結論:
- SSRIは,脳卒中後の回復の強化と関連している可能性があります.
- 現在の証拠基盤は,主に質が悪い.
- これらの発見を検証し,治療効果を正確に推定するために,高品質で大規模なランダム化対照試験が必要です.
さらに関連する動画
04:38A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
Published on: May 22, 2019
9.4K
06:15Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint
Published on: January 9, 2026
209
関連する概念動画
Antidepressant Drugs: Overview
2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.4K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.4K
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Electroconvulsive Therapy
2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K
